Why the study?
Does escalating aspirin dose from 150 mg to 300 mg/day improve platelet inhibition in ACS patients resistant to low-dose aspirin?
Population
50 consecutive patients with unstable angina or non-ST-segment elevation myocardial infarction, and 20…
Comparison
Aspirin 150 mg/day, with dose escalation to 300… vs Intra-individual comparison and healthy controls
Design
Cohort
Authors
Loading...
May support aspirin dose escalation in resistant ACS; leaves open whether this improves clinical outcomes.
Does escalating aspirin dose from 150 mg to 300 mg/day improve platelet inhibition in ACS patients resistant to low-dose aspirin?
Escalating aspirin dose to 300 mg/day overcomes laboratory aspirin resistance in patients with ACS, which is associated with diabetes, hyperlipidemia, and obesity.
SALAMA et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: